NEW YORK, June 17-Phylos said today that it had won a Phase II Small Business Innovation Research grant from the National Institute for Allergy and Infectious Disease.
The $358,326 grant, which lasts through 2004, will allow the company to continue developing a multiplexed cytokine microarray. The company's first SBIR grant for work on this technology was awarded in 1999.
Phylos is working to develop a high-throughput array-based platform to simultaneously measure different cytokine levels using only small amounts of biological sample.
The privately held company is based in Lexington, Mass.
For further information, see Phylos' press release.